Ph.D., Senior Scientist, Dharmacon, a Horizon Discovery Group Company
Emily has managed projects involving the development and application of gene engineering and gene modulation technologies, including Dharmacon™ ON-TARGETplus™ siRNA and Accell™ siRNA, as well as the introduction of Dharmacon™ Edit-R™, the first rationally-designed, genomewide library of synthetic CRISPRs for gene disruption. She received a Ph.D. in Biochemistry from the University of Colorado at Boulder on the structure and function of protein:single-stranded DNA interactions at telomeres. At Dharmacon she has worked extensively on the mechanism, function, specificity, and delivery of RNA interference (RNAi) and its applications. She is an inventor on several issued patents and has authored peer-reviewed publications related to both RNAi and CRISPR-Cas9.
Clinical & Research Tools Showcase: Horizon Discovery
Horizon Discovery is a leader in cell engineering offering inspired cell research solutions.
Synthetic CRISPR RNAs for Functional Gene Studies
Chemically synthesized guide RNAs can be successfully used with the CRISPR-Cas9 system for gene editing and gene activation (CRISPRa). The synthetic CRISPR RNA approach is amenable to loss-of-function and gain-of-function screening in arrayed fashion using complex morphological high-content assays.